Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Rheumatoid Arthritis: Update Bulletin [September 2016]

Product Code:
596200549
Publication Date:
September 2016
Format:
PDF
Price:
€1010

Gain new KOL insights on the latest events happening in rheumatoid arthritis (RA): Topics covered include reactions to the Phase III SIRROUND-D trial, evaluating Janssen/GlaxoSmithKline’s human anti-interleukin (IL)-6 monoclonal antibody, sirukumab; topline results from a second Phase IIb study on Ablynx’s anti-IL-6R nanobody, vobarilizumab; as well as the initiation of the global Phase III (FINCH) programme investigating the efficacy and safety of Galapagos’ Janus kinase 1 (JAK-1) inhibitor, filgotinib.

Business Questions – September 2016 RA Research Update Bulletin

  • What do KOLs think are the advantages and disadvantages of Janssen/GlaxoSmithKline’s human anti-interleukin (IL)-6 monoclonal antibody, sirukumab?
  • Why do KOLs believe that sirukumab may face some approval hurdles, following the presentation of results from the SIRROUND-D trial at EULAR?
  • How do KOLs think sirukumab compares to Roche’s Actemra/RoActemra (tocilizumab), and where do they see the agent being used in the rheumatoid arthritis (RA) treatment paradigm?
  • To what extent does vobarilizumab have the potential to become a successful treatment for RA?
  • To what extent is pricing likely to be a key issue for emerging anti-IL-6 receptor antibodies?
  • How have KOLs’ perceptions of oral Janus kinase (JAK) inhibitors changed and how do they see this drug class being utilised in the future for RA?
  • What are KOLs’ opinions of the Galapagos JAK-1 inhibitor, filgotinib, and how do they think it will fare against competitors such as Pfizer’s Xeljanz (tofacitinib) and Lilly and Incyte’s baricitinib?



customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved